Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

R Ferrari, I Ford, K Fox, JP Challeton, A Correges… - The Lancet, 2020 - thelancet.com
Background Angina might persist or reoccur despite successful revascularisation with
percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in …
被引用次数：66 相关文章
[PDF] servier.com

[PDF][PDF] 2. SYNOPSIS

R Ferrari, I Ford, K Fox, M Marzilli, M Tendera… - …, 2020 - clinicaltrials.servier.com
2. SYNOPSIS Page 1 2. SYNOPSIS Name of Sponsor: IRIS, 50 rue Carnot - 92284
Suresnes Cedex - France (For National Authority Use only) Test drug Name of Finished …

Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

R Ferrari, I Ford, K Fox, JP Challeton, A Correges… - The Lancet, 2020 - thelancet.com
Background Angina might persist or reoccur despite successful revascularisation with
percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in …

Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

R Ferrari, I Ford, K Fox, JP Challeton, A Correges… - Lancet, 2020 - eprints.gla.ac.uk
Background: Angina might persist or reoccur despite successful revascularisation with
percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in …

Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

R Ferrari, I Ford, K Fox, JP Challeton, A Correges… - The Lancet, 2020 - Elsevier
Background Angina might persist or reoccur despite successful revascularisation with
percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in …

Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.

R Ferrari, I Ford, K Fox, JP Challeton… - Lancet (London …, 2020 - europepmc.org
Background Angina might persist or reoccur despite successful revascularisation with
percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in …

Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

R Ferrari, I Ford, K Fox, JP Challeton, A Correges… - 2020 - pubmed.ncbi.nlm.nih.gov
Background Angina might persist or reoccur despite successful revascularisation with
percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in …